Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Debt to Equity (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Debt to Equity for 9 consecutive years, with -$0.06 as the latest value for Q4 2023.

  • For Q4 2023, Debt to Equity fell 133.92% year-over-year to -$0.06; the TTM value through Dec 2023 reached -$0.06, down 133.92%, while the annual FY2023 figure was -$0.06, 133.92% down from the prior year.
  • Debt to Equity hit -$0.06 in Q4 2023 for Cartesian Therapeutics, down from $0.37 in the prior quarter.
  • Across five years, Debt to Equity topped out at $384.79 in Q2 2019 and bottomed at -$5.97 in Q2 2021.
  • Average Debt to Equity over 5 years is $19.52, with a median of $0.19 recorded in 2022.
  • Year-over-year, Debt to Equity soared 39198.5% in 2019 and then crashed 425.67% in 2021.
  • Cartesian Therapeutics' Debt to Equity stood at $2.25 in 2019, then crashed by 161.16% to -$1.38 in 2020, then soared by 182.66% to $1.14 in 2021, then crashed by 83.35% to $0.19 in 2022, then tumbled by 133.92% to -$0.06 in 2023.
  • According to Business Quant data, Debt to Equity over the past three periods came in at -$0.06, $0.37, and $0.35 for Q4 2023, Q2 2023, and Q1 2023 respectively.